Cell line/type | BM-DC (bone marrow derived dendritic cells) |
---|---|
Species | Mouse |
Animal free | Yes |
Product | X-VIVO20; FBS- |
Looney, B. M., Chernatynskaya, A. V., Clare-Salzler, M. J., & Xia, C. Q. (2014). Characterization of bone marrow-derived dendritic cells developed in serum-free media and their ability to prevent type 1 diabetes in nonobese diabetic mice. Journal of blood disorders & transfusion, 5(4). In this study, BM-DC generated in serum-free culture media (X-VIVO20; FBS-) with BM-DC generated in media containing 10% FBS (RPMI1640/10%FBS; FBS+) are compared. It was shown that FBS- BM-DC display a phenotype and cytokine-producing profile distinct from FBS+ BMDC. Additionally, compared to FBS+ BM-DC, evidence was shown of an altered Th cell response induced by FBS- BM-DC. Finally, it was demonstrated that only FBS- BM-DC prevent the onset of T1D and induce increased levels of CD4+Foxp3+ regulatory T cells as well as a long-lasting beta cell-specific T cell response. This study indicates that serum-free media generates a more tolerogenic BM-DC capable of preventing T1D in the NOD mice. X-VIVO20 is a commercial product. The formulation is proprietary. https://www.omicsonline.org/open-access/characterization-of-bone-marrowderived-dendritic-cells-developed-in-serumfree-media-2155-9864.1000206.pdf |
|
Source | Literature - modified commercial product |
Chemically defined > Yes | Yes |
Contains phenol red > Yes | Yes |
Antibiotics free > No | No |